Source: VistaGen Therapeutics, Inc.
Posted: November 12, 2007 8:30 am ET
Summary:
VistaGen Therapeutics, Inc. announced publication of preclinical data suggesting that AV-101, its lead drug candidate for treatment of neurological disorders, may be useful for treating Parkinson's disease.
